Modag
- Company typePrivate
- Founded2013
- HeadquartersWendelsheim, Germany
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Modag does
MODAG GmbH is a privately held German biotechnology company founded in 2013 and headquartered in Wendelsheim, Rhineland-Palatinate, with 11-50 employees. The company develops disease-modifying small-molecule therapeutics and molecular diagnostics targeting pathological alpha-synuclein aggregates in neurodegenerative diseases, primarily Multiple System Atrophy (MSA) and Parkinson's disease.
The company's pipeline is anchored by Emrusolmin (anle138b/TEV-56286), an orally bioavailable oligomer modulator that binds and dissolves toxic alpha-synuclein oligomers and crosses the blood-brain barrier; the compound has completed Phase 1 studies with favorable safety and is currently in a 200-participant Phase 2 trial for MSA, and has received both FDA Orphan Drug (2022) and Fast Track (September 2025) designations. MODAG also markets PD DETECT, the world's first CE-certified (IVDR) biochemical standardized test kit for Parkinson's disease, which detects alpha-synuclein aggregates in cerebrospinal fluid with 97.8% sensitivity and 100% specificity, and is developing a PET tracer program for molecular imaging of synucleinopathies in collaboration with the University of Tübingen, Max Planck Institute, and LMU Munich.
MODAG operates a hybrid revenue model combining licensing and collaboration revenue (exclusive worldwide partnership with Teva Pharmaceutical Industries for Emrusolmin and Sery433, generating upfront payments, development milestones, and royalties), direct diagnostic product sales (PD DETECT) to specialized diagnostic laboratories, university clinics, and research institutions, and non-dilutive research grants (notably $1.4M and $1M awards from The Michael J. Fox Foundation). The company outsources global therapeutic commercialization to Teva while maintaining a focused direct-sales motion for its diagnostic franchise in the DACH region and beyond.
Modag firmographics
Firmographics- Name
- Modag
- Legal name
- MODAG GmbH
- Website
- https://modag.net
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Modag industry classification
Industry- Product category
- Biopharmaceuticals and Diagnostics for Neurodegenerative Diseases
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industries
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)
Keywords
Where Modag is headquartered
LocationHeadquarters
- HQ city
- Wendelsheim
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Modag business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Diagnostic Products: MODAG generates revenue through sale of diagnostic test kits (PD DETECT) to specialized diagnostic laboratories, university clinics, and research institutions.
- Licensing and Collaboration Revenue: Exclusive worldwide licensing and development collaboration with Teva Pharmaceutical for Anle138b (Emrusolmin) and Sery433. MODAG receives upfront payments, development milestones, and royalties on commercial sales from this partnership.
- Research Grants: Funding from The Michael J. Fox Foundation ($1 million grant) and other organizations supporting PET tracer development and clinical research.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Modag product offering
Product offeringCore offering
MODAG develops and commercializes disease-modifying small-molecule therapeutics (Emrusolmin/anle138b) and companion biochemical diagnostics (PD DETECT) targeting pathological alpha-synuclein aggregates in neurodegenerative diseases, specifically Parkinson's disease and Multiple System Atrophy (MSA). The company combines proprietary oligomer modulator chemistry with the world's first CE-IVDR-certified seed amplification assay for Parkinson's diagnosis and is developing PET tracers for molecular imaging of synucleinopathies.
Product overview
MODAG develops a portfolio of therapeutic and diagnostic products for neurodegenerative diseases, centered on two main offerings: Emrusolmin (anle138b/TEV-56286), a disease-modifying small-molecule therapeutic targeting alpha-synuclein oligomers for MSA and Parkinson's disease, and PD DETECT, the world's first CE-certified diagnostic test kit for Parkinson's disease detection via alpha-synuclein seed amplification assay in cerebrospinal fluid. The company also develops PET tracer candidates for molecular imaging of synucleinopathies. This combination of targeted therapeutics and molecular diagnostics represents an integrated approach to addressing neurodegenerative diseases.
Differentiator
Problem solved
Functional benefit
Brands
- PD DETECT: World's first CE-certified biochemical standardized test kit for Parkinson's disease, detecting abnormal alpha-synuclein protein aggregates in cerebrospinal fluid
- Emrusolmin
Products and services
- PD DETECT The world's first CE-IVDR-certified biochemical standardized test kit for Parkinson's disease, designed to detect abnormal alpha-synuclein protein aggregates in cerebrospinal fluid using seed amplification assay (SAA) technology. Delivers 97.8% sensitivity and 100% specificity, enabling earlier and more objective diagnosis by identifying underlying biology before motor symptoms fully manifest. Made available to specialized diagnostic laboratories, university clinics, and research institutions.
- Emrusolmin (anle138b / TEV-56286) A low-molecular-weight drug candidate (oligomer modulator) that specifically binds to toxic oligomer structures of alpha-synuclein, dissolves toxic oligomers, and prevents formation of new oligomers. Can be administered orally and efficiently crosses the blood-brain barrier to act directly intracellularly on toxic oligomers. Developed for Multiple System Atrophy (MSA) and Parkinson's disease in partnership with Teva Pharmaceutical, with FDA Fast Track and Orphan Drug Designations. Currently in Phase 2 clinical study with 200 study participants.
- PET Tracer Program Novel PET tracer compounds that specifically target aggregated alpha-synuclein, enabling direct molecular imaging and quantification of alpha-synuclein deposits in patients' brains for the first time. First tracer candidates have been explored in human PET images in patients with MSA and Parkinson's disease, showing promising preliminary results. Developed in collaboration with University of Tübingen, Max Planck Institute for Multidisciplinary Sciences, and LMU Munich.
Quantifiable outcome
- PD DETECT sensitivity: 97.8%
- +2 more outcomes
Companies that use Modag
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles3 records
Modag technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Modag partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core, major and minor.
- Teva Pharmaceutical Industries Ltd.coreExclusive worldwide licensing and development collaboration for Anle138b (Emrusolmin) and Sery433. Teva received exclusive rights to develop, manufacture, and commercialize these compounds. Both companies jointly develop the drugs for MSA and Parkinson's disease indications, with potential for additional indications based on clinical outcomes. The partnership leverages Teva's neuroscience expertise and global commercial infrastructure.
- University of TübingenmajorAcademic partner in PET tracer program development, contributing to molecular imaging research for synucleinopathies.
- Max Planck Institute for Multidisciplinary Sciences, GöttingenmajorAcademic research partner contributing to PET tracer development and alpha-synuclein research. Foundation partner in company's scientific origins.
- Ludwig-Maximilians-University MunichmajorAcademic partner in PET tracer research and fundamental research origin of MODAG's technology platform. Company was founded based on discoveries from LMU scientists.
- Quotient SciencesminorContract research organization that conducted the Phase 1b study for anle138b in Parkinson's patients in collaboration with University Hospital Nottingham.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
Modag competitors and assessment
Company assessmentDirect peers
- Prothena (Roche partner): Prothena, partnered with Roche, is developing prasinezumab, a monoclonal antibody targeting aggregated alpha-synuclein for Parkinson's disease. It is the most direct mechanistic competitor to MODAG's Emrusolmin in the synucleinopathy space.
- AC Immune: AC Immune is a clinical-stage Swiss biotech developing alpha-synuclein-targeted therapeutics and diagnostics for Parkinson's and related synucleinopathies. It is closely comparable as a European, CNS-focused, alpha-synuclein platform company.
- Amprion: Amprion develops SYNTap, a seed amplification assay for misfolded alpha-synuclein used in Parkinson's diagnosis and clinical research. It is a direct competitor to MODAG's PD DETECT diagnostic kit and is widely used in academic and pharma studies.
Broad incumbents
- Biogen: Biogen developed cinpanemab, an alpha-synuclein antibody for Parkinson's, and has a broad neuroscience portfolio. As a large CNS player pursuing the same target, Biogen is a direct mechanistic and indication peer even though MODAG is far smaller.
- Lundbeck: Lundbeck is a Denmark-based specialty pharmaceutical company focused on CNS disorders including Parkinson's disease. It competes for the same patient population and physician channels that MODAG's therapeutic and diagnostic programs target.
- UCB: UCB is a global biopharma company with a growing neuroscience portfolio including Parkinson's disease programs. It is comparable as a CNS-focused commercial-stage peer whose indication overlap puts it in direct competition for future launch slots.
Emerging players
- Denali Therapeutics: Denali is a clinical-stage neurodegeneration biotech developing small molecules and biologics for Parkinson's and related diseases, including programs that intersect with alpha-synuclein biology. It is a peer in CNS drug development with broader neurodegeneration scope.
- BioArctic: BioArctic is a Swedish biotech developing alpha-synuclein PET tracers and antibody-based therapies for Parkinson's disease. The PET tracer program is a direct peer to MODAG's PET tracer initiative, while their antibody work is mechanistically adjacent.
- Cerevel Therapeutics (AbbVie): Cerevel, now part of AbbVie, is developing CNS therapeutics including assets for Parkinson's disease. It is an emerging peer in the disease-modifying Parkinson's space, with similar neuroscience specialization to MODAG's therapeutic ambition.
Others
- Quotient Sciences: Quotient Sciences is the contract research organization that conducted MODAG's Phase 1b anle138b study in Parkinson's patients. It is an enabling/operational peer in MODAG's drug development workflow rather than a direct competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Modag social profiles
Digital presenceModag compliance and trust
Trust signalCompliance1 record
Modag financial estimates
Financial estimateRevenue estimate
Valuation estimate
Modag leadership team
Management profileNumber of profiles
Profiles3 records
Modag funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Modag M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Modag
What does Modag do?
MODAG develops and commercializes disease-modifying small-molecule therapeutics (Emrusolmin/anle138b) and companion biochemical diagnostics (PD DETECT) targeting pathological alpha-synuclein aggregates in neurodegenerative diseases, specifically Parkinson's disease and Multiple System Atrophy (MSA). The company combines proprietary oligomer modulator chemistry with the world's first CE-IVDR-certified seed amplification assay for Parkinson's diagnosis and is developing PET tracers for molecular imaging of synucleinopathies.
Is Modag a public or private company?
Modag is a private company. It is classified as venture growth investor backed and is currently operating.
When was Modag founded?
Modag was founded in 2013. It employs 11 to 50 people.
Where is Modag based?
Modag is headquartered in Wendelsheim, Germany, in the Europe region.
How does Modag make money?
Three revenue lines are on record. Diagnostic Products are the primary driver. The others are licensing and Collaboration Revenue and research Grants.
Who are Modag's main competitors?
Direct peers on record are Prothena (Roche partner), AC Immune and Amprion. Broad incumbents are Biogen, Lundbeck and UCB. Emerging players are Denali Therapeutics, BioArctic and Cerevel Therapeutics (AbbVie). Quotient Sciences is listed as an others.
Does Modag have an API?
No public API is recorded for Modag.
What industry is Modag in?
Modag's product category is Biopharmaceuticals and Diagnostics for Neurodegenerative Diseases. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.